Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium longum CCDM 372
- Development stage
- Discontinued
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium longum CCDM 372 (also Bl 372) is a specific strain of probiotic bacteria belonging to the subspecies *Bifidobacterium longum subsp. longum*. It was originally isolated from the feces of a healthy, breast-fed infant and is primarily used in research rather than as a commercial product. The active ingredient is the live bacterial organism itself. In laboratory studies, Bl 372 has demonstrated strong immunomodulatory properties, inducing high levels of both pro-inflammatory (TNF-α, IL-6, IFN-γ) and anti-inflammatory cytokines. Its mechanism involves interaction with Toll-like receptor 2 (TLR2) and Nucleotide-binding oligomerization domain-containing protein 2 (NOD2). Despite its in vitro activity, in a preclinical mouse model of dextran sulphate sodium (DSS)-induced colitis, Bl 372 failed to provide a protective effect, unlike the related strain *B. longum* CCM 7952. The strain is deposited in the Culture Collection of Dairy Microorganisms (CCDM) in Prague, Czech Republic.
- Other names
- Bifidobacterium longum subsp. longum CCDM 372
02
Targets
TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on Bifidobacterium longum CCDM 372.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium longum CCDM 372.